ABILENE, Texas & OKLAHOMA CITY--(BUSINESS WIRE)--Receptor Logic, Inc. announced today receipt of a Phase I Small Business Technology Transfer (STTR) Grant from the National Cancer Institute. The grant, entitled “Therapeutic Effectiveness of T-Cell Receptor mimic (TCRm™) Antibodies in Breast Cancer Treatment” will accelerate Investigational New Drug Application enabling studies surrounding lead candidate TCRm antibodies. Receptor Logic develops TCRm monoclonal antibodies (mAbs) that promise access to new patient populations in both oncology and infectious disease indications. They also provide a disruptive and expansive effect in the therapeutic mAb marketplace through new biomarkers that can be targeted for the elimination of diseased tissues.
